These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

153 related articles for article (PubMed ID: 7361542)

  • 1. Improvement of L-dopa induced dyskinesia and of on-off phenomenon by bromocriptine.
    Ludin HP
    Acta Neurol Belg; 1980; 80(1):5-9. PubMed ID: 7361542
    [No Abstract]   [Full Text] [Related]  

  • 2. [Bromocriptine in the treatment of patients with parkinsonism and dyskinesias induced by levodopa].
    Haas JA; Lakke JP
    Ned Tijdschr Geneeskd; 1982 Apr; 126(16):701-5. PubMed ID: 7088202
    [No Abstract]   [Full Text] [Related]  

  • 3. [Oral lisuride in Parkinson's disease].
    Obeso JA; Luquin MR; Martínez Lage JM
    Med Clin (Barc); 1985 Sep; 85(8):307-12. PubMed ID: 4068822
    [No Abstract]   [Full Text] [Related]  

  • 4. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia.
    Muñoz A; Li Q; Gardoni F; Marcello E; Qin C; Carlsson T; Kirik D; Di Luca M; Björklund A; Bezard E; Carta M
    Brain; 2008 Dec; 131(Pt 12):3380-94. PubMed ID: 18952677
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Update on antiparkinsonian agents.
    Weiner M
    Geriatrics; 1982 Sep; 37(9):81-4, 89-91. PubMed ID: 6125455
    [No Abstract]   [Full Text] [Related]  

  • 6. A "combined" levodopa test as a useful method for evaluating the efficacy of dopamine agonists: application to pergolide and bromocriptine.
    Bonnet AM; Serre I; Marconi R; Agid Y; Dubois B
    Mov Disord; 1995 Sep; 10(5):668-71. PubMed ID: 8552122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ropinirole as an adjunct to levodopa in the treatment of Parkinson's disease: a 16-week bromocriptine controlled study.
    Im JH; Ha JH; Cho IS; Lee MC
    J Neurol; 2003 Jan; 250(1):90-6. PubMed ID: 12527999
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of Parkinson's disease: levodopa as the first choice.
    Katzenschlager R; Lees AJ
    J Neurol; 2002 Sep; 249 Suppl 2():II19-24. PubMed ID: 12375059
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Dyskinesias induced by L-DOPA in Parkinson patients].
    García de Yébenes J; Muradas V; Bazán E; Reiriz J; Mena MA
    Arch Neurobiol (Madr); 1985; 48(4):197-209. PubMed ID: 4074075
    [No Abstract]   [Full Text] [Related]  

  • 10. [A clinical analysis of L-dopa induced dyskinesia treated by posteroventral pallidotomy for Parkinson's disease].
    Zhao G; Li Y; Shao M; Ding Y
    Zhonghua Wai Ke Za Zhi; 1999 Aug; 37(8):482-4. PubMed ID: 11829894
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Levodopa-induced dyskinesias in Parkinson's disease: is sensitization reversible?
    Bejjani BP; Arnulf I; Demeret S; Damier P; Bonnet AM; Houeto JL; Agid Y
    Ann Neurol; 2000 May; 47(5):655-8. PubMed ID: 10805339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Disordered respiration as a levodopa-induced dyskinesia in Parkinson's disease.
    Rice JE; Antic R; Thompson PD
    Mov Disord; 2002 May; 17(3):524-7. PubMed ID: 12112201
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Dyskinesia caused by L-DOPA].
    Derkinderen P; Vidailhet M
    Rev Neurol (Paris); 2002 Dec; 158 Spec no 1():S92-101. PubMed ID: 12690668
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Initial therapy for Parkinson's disease: levodopa vs. dopamine receptor agonists.
    Kondo T
    J Neurol; 2002 Sep; 249 Suppl 2():II25-9. PubMed ID: 12375060
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [L-dopa-induced movement disorders in Parkinson disease. Amantadine improves dyskinesia].
    MMW Fortschr Med; 2001 May; 143 Suppl 2():93. PubMed ID: 11434272
    [No Abstract]   [Full Text] [Related]  

  • 16. [The treatment of Parkinson disease using the combination bromocriptine and levodopa].
    Dufresne JJ
    Rev Med Suisse Romande; 1990 Jun; 110(6):559-64. PubMed ID: 2367793
    [No Abstract]   [Full Text] [Related]  

  • 17. Naltrexone, an opiate antagonist, fails to modify motor symptoms in patients with Parkinson's disease.
    Rascol O; Fabre N; Blin O; Poulik J; Sabatini U; Senard JM; Ané M; Montastruc JL; Rascol A
    Mov Disord; 1994 Jul; 9(4):437-40. PubMed ID: 7969211
    [TBL] [Abstract][Full Text] [Related]  

  • 18. De novo administration of ropinirole and bromocriptine induces less dyskinesia than L-dopa in the MPTP-treated marmoset.
    Pearce RK; Banerji T; Jenner P; Marsden CD
    Mov Disord; 1998 Mar; 13(2):234-41. PubMed ID: 9539335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparative study of bromocriptine and levodopa in Parkinson's disease.
    Duvoisin RC; Mendoza MM; Yahr MD
    Adv Biochem Psychopharmacol; 1980; 23():271-5. PubMed ID: 7395618
    [No Abstract]   [Full Text] [Related]  

  • 20. [Aspects of long-term treatment with levodopa alone and levodopa combined with dopa decarboxylase inhibitors].
    Cinca I; Serbănescu A; Tudorache B
    Rev Med Interna Neurol Psihiatr Neurochir Dermatovenerol Neurol Psihiatr Neurochir; 1982; 27(4):261-70. PubMed ID: 6222452
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.